<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We prospectively treated 46 patients with favorable <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> classified as <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA), refractory cytopenia (RC), or <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>These patients received one of two schedules of <z:chebi fb="0" ids="6067">13-Cis-Retinoic Acid</z:chebi> (low dose 80 mg daily for 6 months vs. high dose 200 mg po daily for 3 months), or <z:chebi fb="1" ids="4315">Danazol</z:chebi> (800 mg po daily for 3 months), and were crossed over to the alternative drug in the absence of response or at progression </plain></SENT>
<SENT sid="2" pm="."><plain>Using strict criteria of response we found little objective evidence of activity for either compound </plain></SENT>
<SENT sid="3" pm="."><plain>Only two minor responses were seen among 22 patients treated with low dose 13-CRA, 1 response among 20 cases that received high dose 13-CRA, and 1 partial response and 1 minor response to <z:chebi fb="1" ids="4315">Danazol</z:chebi> among 34 cases </plain></SENT>
<SENT sid="4" pm="."><plain>Neither <z:chebi fb="0" ids="6067">13-Cis-Retinoic Acid</z:chebi> nor <z:chebi fb="1" ids="4315">Danazol</z:chebi> appear active enough in patients with favorable <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> to justify their use </plain></SENT>
</text></document>